International Epi Databases to Evaluate AIDS (IEDEA) in central Africa (Region 9)

描述（由申请人提供）：本申请建议建立一个国际流行病学数据库评估艾滋病（IEDEA）区域中心，以协调区域9 -中非的艾滋病毒数据和数据收集。由北卡罗来纳州三角研究园的三角研究国际（RTI）支持的区域数据中心将设在刚果民主共和国金沙萨的北卡罗来纳州/刚果民主共和国金沙萨公共卫生学院的艾滋病毒/艾滋病临床研究单位。这一多步骤研究和能力建设进程将通过扩大/加强刚果民主共和国公共卫生学院、金沙萨公共卫生学院、RTI和刚果民主共和国国家多部门防治艾滋病方案之间现有的伙伴关系来实现。其他的国际合作者是：⑴比利时安特卫普热带医学研究所; ⑵法国巴黎国家人口研究所，死亡率、流行病学和人口与发展联合研究所; ⑶法国蒙彼利埃蒙彼利埃大学发展研究所和国际卫生系。来自布隆迪、喀麦隆、中非共和国、刚果/布拉柴维尔、刚果民主共和国和卢旺达的第9区域合作者包括艾滋病毒/艾滋病临床医生/护理提供者、国家艾滋病毒方案的代表和国家医学院的教员。我们的区域联盟在一个数据库中有20 200名目前正在接受抗逆转录病毒治疗的患者，并正在跟踪另外46 000名尚不符合接受抗逆转录病毒治疗条件的艾滋病毒感染者。统一本区域的数据是最初的目标。当这一点到位，我们提出的研究议程将包括：（1）确定新的区域适当的艾滋病毒护理模式和监测其疗效的系统;（2）监测哨点人群的抗逆转录病毒药物耐药性;（3）确定在该地区看到的艾滋病毒遗传多样性的高比率对抗逆转录病毒药物耐药性的作用。

DESCRIPTION (provided by applicant): This application proposes to establish an International Epidemiologic Database to Evaluate AIDS (IEDEA) Regional Center to harmonize HIV data and data collection in Region 9 - Central Africa. A Regional Data Center, backstopped by Research Triangle International (RTI), Research Triangle Park, North Carolina will be located in Kinshasa, Democratic Republic of Congo (DRC) at the University of North Carolina/DRC UNC/DRC) HIV/AIDS Clinical Research Unit at the Kinshasa School of Public Health. This multi-step research and capacity building process will occur through regional expansion/reinforcement of the existing partnership between the UNC's School of Public Health, the Kinshasa School of Public Health, RTI and the DR Congo's Programme National Multisectoriel de Lutte centre le SIDA (PNMLS). Additional international collaborators are: (1) Institute of Tropical Medicine in Antwerp, Belgium; (2) Institut National d'Etudes Demographiques Research Unites Mortalite Sante Epidemiologie et Population and Developpement, Paris, France; (3) Institut de Recherche pour le Developpement and Department of International Health, University of Montpellier, Montpellier France. Region 9 collaborators from Burundi, Cameroon, Central African Republic, Congo/Brazzaville, Democratic Republic of Congo, and Rwanda include HIV/AIDS clinicians /care providers, representatives of national HIV programs, and faculty from national medical schools. Our regional consortium has 20,200 patients currently on ARV's in a database and are following an additional 46,000 HIV-infected individuals who are not yet eligible to receive ART treatment. Harmonization of data across our region is the initial goal. When this is in place, our proposed research agenda will include: (1) Identify new region-appropriate models of HIV care and systems for monitoring its efficacy; (2) Monitor sentinel populations for ARV resistance; (3) Determine the role the high rate of genetic diversity for HIV seen in this region plays on ARV resistance.